文献速递炎症性肠病

克罗恩病的早期干预:迈向疾病修饰试验

Early intervention in Crohn's disease: towards disease modification trials.
PubMed 文献 · Gut · 2017-09-05

克罗恩病(CD)是慢性进展性破坏性炎症性肠病。越来越多证据表明,对病程<2年且无并发症的患者早期使用免疫抑制剂和生物制剂可能显著降低并发症风险并延长缓解时间,但需前瞻性疾病修饰试验确认。本文综述成人CD早期干预文献并提出未来疾病修饰试验的标准。

要点

  • 病程<2年且无并发症的CD患者早期使用免疫抑制剂或生物制剂可能降低并发症风险并延长缓解时间。
  • 快速控制疾病可能有效预防疾病进展,并允许减量甚至停药,减少长期不良事件和医疗费用。
  • 需前瞻性疾病修饰试验确认这些初步结果,本文提出未来试验的标准。

核心结论

  • 早期使用疾病修饰药物(如生物制剂)可能实现完全疾病控制、预防进展、保护免受不可逆损伤并恢复正常生活质量。
  • 需前瞻性疾病修饰试验确认这些初步结果。

研究设计与样本

  • 综述成人克罗恩病早期干预相关文献并提出未来疾病修饰试验标准。

主要发现

  • 对病程<2年且无并发症的CD患者使用免疫抑制剂和生物制剂可能显著降低并发症风险并增加缓解时间。
  • 快速控制疾病可能有效预防疾病进展,并允许减量或甚至停药,减少长期不良事件风险和医疗费用。

局限性

  • 需前瞻性疾病修饰试验确认这些初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Crohn's disease (CD) is a chronic progressive destructive inflammatory bowel disease. As in rheumatoid arthritis, there is increasing evidence that early treatment initiation with disease-modifying agents, such as biological drugs, may lead to complete disease control, prevention of disease progression thus protecting against irreversible damage and restoration of normal quality of life. Data from randomised clinical trials with immunosuppressants and biologics suggest that treating patients with a disease duration of <2 years and an absence of complications may significantly reduce the risk for complications and increase time in remission in patients with CD. Moreover, rapid disease control may effectively prevent disease progression and allow dose reduction or even withdrawal of treatment, reducing the risk of long-term adverse events and healthcare costs. However, prospective disease modification trials are needed to confirm these initial results. Here we review the literature regarding early intervention in adult patients with CD and propose criteria for future disease modification trials.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017. PMID: 28874419. doi:10.1136/gutjnl-2017-314519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。